DK4267144T3 - Topisk braf inhibitorsammensætninger til behandling af egfrnedstrøms effektor-inducerede reaktioner - Google Patents
Topisk braf inhibitorsammensætninger til behandling af egfrnedstrøms effektor-inducerede reaktionerInfo
- Publication number
- DK4267144T3 DK4267144T3 DK21909623.7T DK21909623T DK4267144T3 DK 4267144 T3 DK4267144 T3 DK 4267144T3 DK 21909623 T DK21909623 T DK 21909623T DK 4267144 T3 DK4267144 T3 DK 4267144T3
- Authority
- DK
- Denmark
- Prior art keywords
- braf inhibitor
- downstream effector
- inhibitor compositions
- induced reactions
- treating egfr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063130483P | 2020-12-24 | 2020-12-24 | |
| PCT/IB2021/000799 WO2022136912A1 (en) | 2020-12-24 | 2021-11-19 | Topical braf inhibitor compositions for treatment of egfr downstream effectors - induced reactions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4267144T3 true DK4267144T3 (da) | 2026-03-30 |
Family
ID=82157434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21909623.7T DK4267144T3 (da) | 2020-12-24 | 2021-11-19 | Topisk braf inhibitorsammensætninger til behandling af egfrnedstrøms effektor-inducerede reaktioner |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230321106A1 (da) |
| EP (1) | EP4267144B1 (da) |
| CN (1) | CN116669739A (da) |
| CA (1) | CA3203021A1 (da) |
| DK (1) | DK4267144T3 (da) |
| ES (1) | ES3060285T3 (da) |
| IL (1) | IL303804A (da) |
| MX (1) | MX2023007547A (da) |
| WO (1) | WO2022136912A1 (da) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5833007B2 (ja) * | 2009-08-31 | 2015-12-16 | ドクター・レディーズ・ラボラトリーズ・リミテッド | ステロイドを含む局所製剤 |
| ES2947237T3 (es) * | 2016-03-10 | 2023-08-03 | Lutris Pharma Ltd | Uso de inhibidores de BRaf para el tratamiento de reacciones cutáneas |
| WO2017223245A1 (en) * | 2016-06-21 | 2017-12-28 | The Regents Of The University Of California | Wound healing using braf inhibitors |
| WO2019026065A2 (en) * | 2017-07-29 | 2019-02-07 | Lutris Pharma Ltd. | NOVEL BRAF INHIBITORS AND THEIR USE FOR THE TREATMENT OF SKIN REACTIONS |
| WO2019070920A1 (en) * | 2017-10-03 | 2019-04-11 | Collidion, Inc. | COMPOSITIONS, METHODS AND USES FOR ENHANCING A ZONE OF SKIN OR HAIR |
| IL285560B2 (en) * | 2019-02-12 | 2024-04-01 | Lutris Pharma Ltd | Topical preparations containing a BRAF inhibitor for the treatment of dermatitis as a result of radiation |
-
2021
- 2021-11-19 CA CA3203021A patent/CA3203021A1/en active Pending
- 2021-11-19 IL IL303804A patent/IL303804A/en unknown
- 2021-11-19 EP EP21909623.7A patent/EP4267144B1/en active Active
- 2021-11-19 WO PCT/IB2021/000799 patent/WO2022136912A1/en not_active Ceased
- 2021-11-19 MX MX2023007547A patent/MX2023007547A/es unknown
- 2021-11-19 DK DK21909623.7T patent/DK4267144T3/da active
- 2021-11-19 ES ES21909623T patent/ES3060285T3/es active Active
- 2021-11-19 CN CN202180087175.9A patent/CN116669739A/zh active Pending
-
2023
- 2023-06-13 US US18/334,084 patent/US20230321106A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES3060285T3 (en) | 2026-03-25 |
| MX2023007547A (es) | 2023-08-10 |
| EP4267144A4 (en) | 2024-10-23 |
| WO2022136912A1 (en) | 2022-06-30 |
| CN116669739A (zh) | 2023-08-29 |
| EP4267144B1 (en) | 2025-12-31 |
| CA3203021A1 (en) | 2022-06-30 |
| IL303804A (en) | 2023-08-01 |
| US20230321106A1 (en) | 2023-10-12 |
| EP4267144A1 (en) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3986897T3 (da) | EGFR-hæmmer til cancerbehandling | |
| EP4197538A4 (en) | Egfr inhibitor | |
| DK4334298T3 (da) | Ureaderivater, der kan anvendes til behandling af cancer | |
| CY1123557T1 (el) | Συνθεσεις και μεθοδοι για την αναστολη της δραστηριοτητας της αργινασης | |
| MA54953A (fr) | Composés, compositions et procédés | |
| IL288061A (en) | Compounds and methods for the treatment of covid-19 | |
| DK4126066T3 (da) | Sammensætninger og fremgangsmåder til behandling af muskeldystrofi | |
| EP3976595A4 (en) | SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREOF | |
| EP3877381A4 (en) | BENZAMIDES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | |
| EP4358732A4 (en) | PROCEDURE | |
| PT3837256T (pt) | Compostos e composições de ureia como inibidores de smarca2/brm-atpase | |
| MA55087A (fr) | Compositions et procédés de traitement de laminopathies | |
| EP4037709A4 (en) | KNOTTINE-IMMUNOSTIMULANT CONJUGATES AND RELATED COMPOSITIONS AND METHODS | |
| EP3908319A4 (en) | Metalloenzyme inhibitor compounds | |
| BR112018008506B8 (pt) | Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos | |
| DK3478284T3 (da) | Forbindelser og sammensætninger til behandling af cancer | |
| DK4103178T3 (da) | Fremgangsmåder til behandling af fabrys sygdom | |
| DK3952858T3 (da) | Fremgangsmåde til behandling af tumorer | |
| EP4392415A4 (en) | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | |
| IL309662A (en) | Compositions and methods for treating cancers | |
| DK3634394T3 (da) | Sammensætninger til behandling af neurogenerative sygdomme | |
| ZA202106581B (en) | Use of topical braf inhibitor compositions for treatment of radiation dermatitis | |
| EP4103176A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR PROTEIN DEGRADATION | |
| EP4087585A4 (en) | COMPOSITIONS AND METHODS FOR PREVENTING CANCER RECURRENCE | |
| EP4065725C0 (en) | METHODS, COMPOSITIONS AND SYSTEMS FOR ENHANCING THE BINDING OF METHYLATED POLYNUCLEOTIDES |